Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
SGMO
$8.52
Sangamo Therapeutics
($.03)
(.35%)
SGMO
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus: ($0.34)
Revenue: $28.34 Mil
Wednesday
Nov 3
4:00 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, August 05, 2021
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
What do you expect when SGMO reports earnings?
Beat
Meet
Miss
Where is SGMO's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$8.98
$8.87
$8.69
$8.58
Support
$8.40
$8.29
$8.11
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States.
Peers
Biogen
Amgen
Neurocrine Biosciences
Gilead Sciences
Bluebird Bio
Seagen Inc.
BioCryst Pharmaceuticals
Repligen
Bio-Techne
Novavax
Expectations
›
Sangamo Therapeutics
